CASP3 and Miyoshi myopathy: The selective MM cell-killing ability of single-agent bortezomib has been demonstrated in vitro in human MM cell lines [19]; in these studies, induction of apoptosis was quantified by analysis of cell cycle arrest, DNA fragmentation, and caspase 3 cleavage.